Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis

Wenhai Fu, Wenjun He, Yuexin Li, Yangxiao Chen, Jingyi Liang, Hui Lei, Lin Fu, Yanghang Chen, Ni Ren, Qian Jiang, Yi Shen, Ran Ma, Tao Wang, Xinni Wang, Nuofu Zhang, Dakai Xiao and Chunli Liu

Department of Medicine, First Clinical School, Guangzhou Medical University, Guangzhou, China; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China

ABSTRACT
Background: Pulmonary arterial hypertension (PAH) is a severe and fatal clinical syndrome characterized by high blood pressure and vascular remodeling in the pulmonary arterioles, which is also a rapidly progressing disease of the lung vasculature with a poor prognosis. Although PAH medication made great advances in recent years, the efficacy and safety of the medication are unsatisfactory. Therefore, we aimed to update and expand previous studies to explore the efficacy and safety of PAH-targeted medications. Methods: Relevant articles were searched and selected from published or publicly available data in PubMed, Cochrane Library, CNKI, PsycInfo, and MEDLINE (from inception until October 1st, 2020). To assess the efficacy and safety of PAH therapies, five efficacy outcomes [6-minute walking distance (6MWD), mean pulmonary arterial pressure (mPAP), WHO functional class (WHO FC) improvement, clinical worsening, death] and two safety outcomes [adverse events (AEs), serious adverse events (SAEs)] were selected. And 6MWD was regarded as the primary efficacy outcome. Results: 50 trials included with 10 996 participants were selected. In terms of efficacy, all targeted drugs were more effective than placebo. For 6MWD, Bosentan + Sildenafil, Sildenafil, Bosentan + Iloprost were better than others. Bosentan + Iloprost and Bosentan + Sildenafil were better for mPAP. Bosentan + Iloprost and Ambriksentan + Tadalafil were more effective in improving WHO FC. Bosentan + Tadalafil and Bosentan + Iloprost had the Ambriksentan probability to reduce the incidence of clinical worsening. It is demonstrated that Ambriksentan had clear benefits in reducing all-cause mortality. In terms of safety, no therapies had been shown to reduce the incidence of SAEs significantly, and Ambriksentan + Tadalafil significantly increased the incidence of AEs. Conclusions: Phosphodiesterase 5 inhibitor (PDE5i) + Endothelin Receptor Antagonists (ERA) seems to be better therapy for PAH. Prostacyclin analogs (ProsA) + ERA appear promising, though additional data is warranted.

Registration PROSPERO CRD42020218818.

Introduction

Pulmonary arterial hypertension (PAH) is a lethal disease characterized by high pulmonary arterial pressure (Dodson et al., 2018), which is also a rapidly progressing disease of the lung vasculature with a poor prognosis (Prins and Thenappan, 2016). When left untreated, it may ultimately lead to right heart failure and death (Querejeta Roca et al., 2015). The therapeutic methods of PAH are intricate, including PAH risk assessment, acute pulmonary vascular reaction assessment, general treatment, supportive therapy, targeted drug therapy, interventional and surgical treatment, and efficacy evaluation (Kusunose et al., 2019). With the development of the research in pathogenesis and pathophysiology of PAH, there has recently been substantial progress in developing new therapeutic strategies for the management of patients with PAH (Montani et al., 2014). The approved targeted drugs including Endothelin Receptor Antagonists (ERA) (Bosentan, Ambriksentan, Macitentan), Phosphodiesterase 5 inhibitor (PDE5i) (Sildenafil, Tadalafil, Vardenafil, soluble guanylate cyclase (SGC) (Riociguat), Prostacyclin analogue (ProsA) (Epoprostenol, Iloprost, Treprostinil, Beraprost, Selexipag) (O’Connell et al., 2013). These targeted drugs have been shown to have the ability of relieving PAH symptoms and further improving exercise capacity and...
hemodynamics (Lajoie et al., 2016; Zheng et al., 2018). Although significant PAH treatment advances have been made in recent years, the effectiveness and safety are unsatisfactory. Therefore, clinicians need sufficient evidence to make the optimal choice for each PAH patient. Thus, to provide a more convincing guideline for the clinical practice of PAH, our goal is to perform a network meta-analysis systematic review combining direct and indirect evidence to explore targeted drugs’ efficacy and safety.

Methods

The systematic review protocol has been registered with the International Prospective Register of Systematic Reviews Database (PROSPERO). The registration number is CRD42020218818.

Search strategy

We searched the database including PubMed, Cochrane Library, CNKI, PsycInfo, and MEDLINE (from inception until October 1, 2020). We used the following terms together with their corresponding synonyms in our searches: (‘pulmonary arterial hypertension’ OR ‘PAH’) AND (‘Bosentan’ OR ‘Ambrisentan’ OR ‘Macitentan’ OR ‘Sildenafil’ OR ‘Tadalafil’ OR ‘Vardenafil’ OR ‘Riociguat’ OR ‘Epoprostenol’ OR ‘Iloprost’ OR ‘Trentol’ OR ‘Beraprost’ OR ‘Selexipag’). We screened the reference list for each relevant article one by one to check their qualifications. Then, two investigators retrieved the relevant articles independently. If there had been different opinions, we settled them through discussion. Additionally, the literature review searches will be updated at the end of the process.

Selection criteria

Studies will be included if they were conforming to the following criteria: (1) randomized controlled trials (RCTs) as study design and comparator was either a PAH-targeted drug or placebo; (2) patients were diagnosed as group 1 PH according to the clinical classification of PAH; (3) patients with PAH (group 1 PH) were primarily adults (allowing patients under 14 years old if most of the participants were adults); (4) the minimum follow-up period was 12 weeks.

The exclusion criteria were: (1) non-RCTs, studies with insufficient data, duplicated publications, conference reports, systematic reviews; (2) trials restricted neonatal or pediatric patients; (3) studies on patients from the remaining WHO PH groups or no data for PAH were available.

Data extraction

Two investigators independently reviewed all relevant articles to perform the data retrieval and eligibility assessment with standardized data abstraction forms. Any disagreement was resolved after mutual agreement and discussion or with the help of the third investigator.

Outcome measures

The effective primary outcome of this network meta-analysis was 6MWD. The effective secondary outcomes included mPAP, WHO functional class (WHO FC) improvement, clinical worsening, and all-cause death. The safety outcomes were AEs and SAEs.

In terms of continuous outcome measures (i.e. 6MWD, mPAP), differences in the mean change from baseline (mean change) separately for the treatment and comparator arm and their standard deviation (SD) were extracted. When the mean and SD are not available, all data in the manuscript are reported in the forms of median [range, size of a sample or the sample], median [interquartile range] and 95% CIs (P value) (Hozo et al., 2005; Wan et al., 2014). For dichotomous outcomes (i.e. death, clinical worsening, WHO FC improvement, AEs, SAEs), the total number of patients (N) and the number of patients with events (r) were extracted or calculated for each treatment.

Quality assessment

The risk of bias for individual studies was assessed according to the Cochrane Handbook method for Systematic Reviews of Interventions. The following domains were evaluated: random sequence generation (selections bias), allocation concealment (selections bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias. The overall risk of bias will be determined as low (all items were low risk, or at least five items were low risk and the remaining two unclear), unclear (>2 items were unclear risk), and high (>1 quality dimension suggested high bias) (Wei et al., 2016).

Network meta-analysis

A network evidence diagram was constructed by using STATA16 software. A Bayesian network meta-analysis was used to compare the differences between different interventions. Results were presented as the pooled estimates of odds ratios (ORs) or weighted mean difference (WMD) (95% CI). The node splitting method was used to determine the consistency between direct or indirect evidence (Zhang and Xiao, 2018). Based on the results, to choose a consistent or inconsistent model, a consistency model was selected for further analysis when the results of node-splitting are inconsistent model, a consistency model was selected for further analysis when the results of node-splitting are inconsistent. The SUCRA was plotted for ranking, where a lower SUCRA value indicated a higher probability of intervention’s probability. The SUCRA value ranges from 0 to 1. The larger the SUCRA value, the better the rank of the intervention. In contrast, the SUCRA was plotted for ranking, where a lower SUCRA value indicated a higher risk of adverse events (AEs). However, the interpretation of SUCRA needs to be prudently interpreted based on a statistical difference. We evaluated whether treatment effects for 6MWD
were robust in subgroup analyses by using a method of administration. Subgroup analyses were conducted by using the Bayesian Markov Chain Monte Carlo method in OpenBUGS. The sensitivity assessment of our conclusions was restricted by the multicenter.

Results

The search identified 8375 articles, and 137 potentially qualified articles were retrieved. Finally, a total of 50 articles with 10,996 participants were included in the study. The selection process details were shown in Figure 1. The primary characteristics of these studies were shown in Table 1. Patient characteristics of subjects included in the selected RCTs were shown in Table 2. Changes in 6MWD were shown in Supplementary Table 1. Figure 2 demonstrated an assessment of bias risk by the Cochrane risk of bias tool.

Statistical analysis

The node-splitting method is used for inconsistency testing to analyze all outcome indicators. The results indicated that all direct and indirect evidence was consistent, suggesting that meta-analysis should be performed using a concordant model ($P > 0.05$). The node-splitting method-specific results are depicted in Supplementary Table 2. The network of comparisons for efficacy and safety were shown in Figure 3.

The primary efficacy outcome: 6MWD

In terms of 6MWD, a total of 40 studies were included. The results showed that Bosentan combined with Sildenafil (WMD, 98.53, 95% CI, 69.13–127.94), Sildenafil (WMD, 79.24, 95% CI, 49.05–109.42), Bosentan combined with Iloprost (WMD, 69.16, 95% CI, 46.39–91.93), Bosentan combined with Tadalafil (WMD, 67.48, 95% CI, 44.41–90.55), Bosentan (WMD, 55.68, 95% CI, 43.46–67.90), Epoprostenol (WMD, 46.94, 95% CI, 32.36–61.52), Beraprost (WMD, 34.04, 95% CI, 9.18–58.91), Ambrisentan combined with Tadalafil (WMD, 24.86, 95% CI, 10.63–39.09), Riociguat (WMD, 23.94, 95% CI, 10.06–37.83), Macitentan (WMD, 17.10, 95% CI, 1.09–33.11) and Troprostacyclin (WMD, 14.77, 95% CI, 6.91–22.63) were statistically superior to placebo. According to the SUCRA, Bosentan combined with Sildenafil (99.0%), Sildenafil (87.5%), Bosentan combined with Iloprost (82.3%), and Bosentan combined with Tadalafil (80.9%) have the highest probabilities of being the best treatment options. The results of subgroup analysis showed that the mode of administration had no significant effect on the 6MWD. WMD for 6MWD from network meta-analysis was shown in Supplementary Table 3. SUCRA results were demonstrated in Table 3. The results of subgroup analysis were shown in Supplementary Table 4.

The secondary efficacy outcomes: mPAP

In terms of mPAP, a total of 22 studies were included. The results showed that Bosentan combined with Iloprost (WMD, −13.89, 95% CI, −19.56–8.22), Bosentan combined with Sildenafil (WMD, −10.80, 95% CI, −19.07–2.53), Bosentan...
Table 1. The main characteristics of the included randomized controlled trials.

| First author (year) | Study design | Aetiology | Outcome assessment time | Treatment | Comparator |
|---------------------|--------------|-----------|-------------------------|-----------|------------|
| McLaughlin et al. (2018) | MC, DB | IPAH, APAH | 12 weeks | Epoprostenol (2 ng/kg) | Placebo |
| White et al. (2019) | MC, DB | IPAH, APAH | 24 weeks | Epoprostenol (0.125 mg) | Placebo |
| Jing et al. (2013) | MC, DB | IPAH, APAH | 12 weeks | Epoprostenol (1—12 mg) | Placebo |
| Huremath et al. (2010) | MC, DB | IPAH, APAH | 12 weeks | Epoprostenol (4—100 ng/kg/min) | Placebo |
| Simoneau et al. (2012) | MC, DB | IPAH, APAH, HPAH | 17 weeks | Selexipag (400–800 ug) | Placebo |
| Coghlan et al. (2018) | MC, DB | IPAH, APAH, Drugs and toxins induced | 12 weeks | Selexipag (200–1600 ug) | Placebo |
| Janssens et al. (2019) | MC, DB | IPAH, APAH | 26 weeks | Sildenafil (100 mg) | Placebo |
| Galie et al. (2009) | MC, DB | IPAH, APAH | 12 weeks | Tadalafil (20 mg) | Placebo |
| Badesch et al. (2000) | MC, DB | APAH | 24 weeks | Tadalafil (10 mg) | Placebo |
| Galie et al. (2002) | MC, DB | IPAH, APAH, Drugs and toxins induced | 12 weeks | Ambrisentan (5 mg) | Placebo |
| Galie et al. (2008) | MC, DB | IPAH, APAH, Drugs and toxins induced | 12 weeks | Ambrisentan (5 mg) | Placebo |
| White et al. (2019) | MC, DB | IPAH, APAH | 24 weeks | Ambrisentan (10 mg) + Tadalafil (40 mg) | Placebo |
| Galie et al. (2015) | MC, DB | IPAH, APAH, Drugs and toxins induced | 16 weeks | Ambrisentan (10 mg) + Tadalafil (40 mg) | Placebo |
| Kuwana et al. (2020) | MC, DB | HPAH | 16 weeks | Ambrisentan (10 mg) + Tadalafil (40 mg) | Placebo |
| Baughman et al. (2014) | MC, DB | HPAH | 16 weeks | Bosentan (62.5 mg up to 125 mg) | Placebo |
| Rubin et al. (2002) | MC, DB | APAH | 12 weeks | Bosentan (125 mg) | Placebo |
| Galie et al. (2002) | MC, DB | APAH | 16 weeks | Bosentan (62.5–125 mg) | Placebo |
| Badesch et al. (2002) | MC, DB | APAH | 12 weeks | Bosentan (62.5–125 mg) | Placebo |
| Galie et al. (2008) | MC, DB | IPAH, APAH | 32 weeks | Bosentan (62.5–125 mg) | Placebo |
| Ni and Wa (2018) | SC, DB | APAH | 24 weeks | Bosentan (62.5–125 mg) | Placebo |
| McLaughlin et al. (2015) | MC, DB | IPAH, APAH, HPAH, Drugs and toxins induced | 32 weeks | Sildenafil (20 mg) + Bosentan (125 mg) | Placebo |
| Iversen et al. (2010) | SC, DB | APAH | 12 weeks | Sildenafil (25 mg up to 50 mg) + Bosentan (62.5 mg up to 125 mg) | Placebo |
| Vizza et al. (2017) | MC, DB | IPAH, HPAH | 12 weeks | Sildenafil (20 mg) + Bosentan (62.5 mg or 125 mg) | Placebo |
| Ling-Yun et al. (2016) | SC, DB | APAH | Ambiguous | Sildenafil (20 mg) + Bosentan (125 mg) | Placebo |
| Pulido et al. (2013) | MC, DB | IPAH, APAH, HPAH, Drugs and toxins induced | 24 weeks | Macitentan (3 mg and 10 mg) | Placebo |
| Sitbon et al. (2019) | SC, DB | APAH | 12 weeks | Macitentan (10 mg) | Placebo |
| Jansa and Pulido (2018) | SC, DB | IPAH, APAH, HPAH, Drugs and toxins induced | 24 weeks | Macitentan (10 mg) | Placebo |
| De-Zhen and An-Meng (2020) | SC, NR | IPAH, APAH | 24 weeks | Tadalafil (10 mg up to 20 mg) + Bosentan (62.5 mg up to 125 mg) | Placebo |
| Jian-zhou et al. (2018) | SC, NR | APAH | 24 weeks | Tadalafil (10 mg) + Bosentan (62.5 mg up to 125 mg) | Placebo |
| Galie et al. (2002) | MC, DB | IPAH, APAH | 12 weeks | Beraprost (80 ± 35 ug) | Placebo |
| McLaughlin et al. (2006) | MC, DB | IPAH, APAH | 12 weeks | Iloprost (5 ug) + Bosentan (125 mg) | Placebo |
| Hoeper et al. (2006) | MC, DB | IPAH | 12 weeks | Iloprost (5 ug) + Bosentan (125 mg) | Placebo |
| Badesch (2000) | MC, DB | APAH | 12 weeks | Epoprostenol (5 ng/kg) | Placebo |
| Barst et al. (1996) | MC, NR | IPAH | 12 weeks | Epoprostenol (2 ng/kg) | Placebo |
| Barst (1997) | MC, NR | IPAH | 48 weeks | Epoprostenol (2 ng/kg) | Placebo |

(continued)
Table 5. SUCRA results were demonstrated in Table 3.

Table 1. Continued.

| First author (year)          | Study design | Aetiology          | Outcome assessment time | Treatment                                                                 | Intervention | Comparator |
|------------------------------|--------------|--------------------|-------------------------|---------------------------------------------------------------------------|--------------|------------|
| Cheitlin (2006)              | SC, DB       | IPAH, APAH         | 12 weeks                | Slidenafl (40 mg)                                                         | 67           | Placebo    |
| Wilkins et al. (2005)        | SC, DB       | IPAH, APAH         | 14 weeks                | Bosentan (62.5 mg up to 75 mg)                                            | 12           | Placebo    |
| Ronald (2004)                | MC, DB       | APAH               | 12 weeks                | Treprostalin (1.4 mg/kg up to 22.5 mg/kg)                                  | 41           | Placebo    |
| Tapson et al. (2012)         | MC, DB       | IPAH, APAH, HPAH   | 16 weeks                | Treprostalin (2.5 mg/kg up to 22.5 mg/kg)                                  | 174          | Placebo    |
| Simonneau et al. (2014)      | MC, DB       | IPAH, HPAH, Drugs  | 16 weeks                | Beraprost (2000 mg)                                                      | 60           | Placebo    |
| Barst et al. (2003)          | MC, DB       | APAH               | 48 weeks                | Epoprostenol (2 mg/kg/min up to 14 ± 2 mg/kg/min) + Bosentan (62.5 mg up to 125 mg) | 22           | Placebo    |
| Humbert et al. (2004)        | MC, DB       | IPAH, APAH         | 16 weeks                | Sildenafil (25 mg)                                                       | 41           | Sildenafil (20 mg) + Bosentan (62.5 mg) |
| Jian-Yong et al. (2018)      | SC, NR       | APAH               | 12 weeks                | Sildenafil (25 mg)                                                       | 157          | Placebo    |
| Tapson et al. (2013)         | MC, DB       | IPAH, APAH, HPAH   | 16 weeks                | Treprostalin (2.5 mg/kg up to 22.5 mg/kg)                                  | 134          | Placebo    |
| Zhuang et al. (2014)         | MC, DB       | IPAH, APAH, HPAH   | 16 weeks                | Ambrisentan (10 mg) + Tadalafil (40 mg)                                    | 60           | Placebo    |
| Jing et al. (2011)           | MC, DB       | IPAH, APAH         | 12 weeks                | Vardenafil (5 mg)                                                        | 44           | Placebo    |
| Barst et al. (2011)          | MC, DB       | IPAH, APAH, HPAH   | 16 weeks                | Bosentan (20 or 40 mg) + Tadalafil (40 mg)                                 | 42           | Bosentan (20 or 40 mg) |
| Gatzoulis et al. (2019)       | MC, DB       | APAH               | 16 weeks                | Macitentan (10 mg)                                                       | 111          | placebo    |
| Rosenkranz et al. (2015)     | MC, DB       | APAH               | 12 weeks                | Riociguat (2.5 mg)                                                       | 13           | placebo    |
| Humbert et al. (2017)        | MC, DB       | APAH               | 12 weeks                | Riociguat (2.5 mg)                                                       | 71           | placebo    |
| Ghofrani et al. (2013)       | MC, DB       | IPAH, HPAH         | 12 Weeks               | Riociguat (2.5 mg)                                                       | 254          | placebo    |

APAH: Connective tissue disease, Human immunodeficiency virus (HIV) infection, Portal hypertension, Congenital heart disease, and Schistosomiasis; DB: double-blind; HPAH: heritable pulmonary arterial hypertension; IPAH: idiopathic pulmonary arterial hypertension; MC: many centers; NR: not reported; SC: single-center.

(WMD, 5.89, 95% CI, −9.84–−1.9), Macitentan (WMD, −5.76, 95% CI, −9.34–−2.19), Epoprostenol (WMD, −4.14, 95% CI, −7.99–−0.29) and Riociguat (WMD, −3.91, 95% CI, −7.65–−0.17) were superior to placebo for lowering mPAP. According to SUCRA, Bosentan combined with Iloprost ranked first among all the treatments (SUCRA of 95.9%), followed by Bosentan combined with Sildenafil (SUCRA of 84.4%). WMD for mPAP from network meta-analysis was shown in Supplementary Table 5. SUCRA results were demonstrated in Table 3.

WHO FC improvement

As far as the WHO FC improvement, there were 21 studies included in total. The improvement was statistically significant for Bosentan combined with Iloprost (OR, 14.81, 95% CI, 2.83–77.58), Ambrisentan combined with Tadalafil (OR, 4.02, 95% CI, 1.26–12.82), Tadalafil (OR, 3.14, 95% CI, 1.05–9.42), Sildenafil (OR, 2.58, 95% CI, 1.18–5.66), Bosentan (OR, 2.00, 95% CI, 1.30–3.06), Riociguat (OR, 1.59, 95% CI, 1.07–2.36) versus Placebo. In the SUCRA, Bosentan combined with Iloprost ranked first among all the treatments (SUCRA: 95.4%), followed by Ambrisentan combined with Tadalafil (SUCRA: 79.8%). OR for WHO FC improvement from network meta-analysis was shown in Supplementary Table 6. SUCRA results were demonstrated in Table 3.

Clinical worsening

In the case of Clinical Worsening, a sum of 24 studies were included. In network meta-analysis, the proportion of clinical worsening was significantly reduced in Bosentan combined with Tadalafil (OR, 0.08, 95% CI, 0.01–0.55), Bosentan combined with Iloprost (OR, 0.09, 95% CI, 0.02–0.48), Vardenafil (OR, 0.09, 95% CI, 0.01–0.92), Bosentan (OR, 0.21, 95% CI, 0.10–0.43), Ambrisentan combined with Tadalafil (OR, 0.30, 95% CI, 0.16–0.58), Sildenafil (OR, 0.31, 95% CI, 0.15–0.68), Tadalafil (OR, 0.34, 95% CI, 0.17–0.67) and Treprostiniol (OR, 0.66, 95% CI, 0.45–0.97), versus Placebo. Based on the NMA model for reducing the occurrence of clinical worsening, targeted drugs for pulmonary hypertension (PH) can be ranked as follows: Bosentan combined with Tadalafil (SUCRA 85.5%) > Bosentan combined with Iloprost (SUCRA 85.0%). OR for Clinical Worsening from network meta-analysis were shown in Supplementary Table 7. SUCRA results were demonstrated in Table 3.

All-cause death

For efficacy outcomes of all-cause death, 42 studies were included in total. The results showed that Ambrisentan (OR, 0.29, 95% CI, 0.11–0.78) and Treprostiniol (OR, 0.58, 95% CI, 0.41–0.84) were statistically superior to placebo. According to
Table 2. Patient characteristics of subjects included in the selected randomized controlled trials.

| First author (year) | Age, years, mean (SD) | Sex, % | Cause of PAH, n | Baseline 6MWD, m Mean (SD) | WHO/NYHA functional class, n |
|---------------------|-----------------------|--------|-----------------|---------------------------|-----------------------------|
|                     |                       | Male   | Female         | IPAH Other | Male   | Female | IPAH Other | Male   | Female | IPAH Other | I      | II      | III | IV    | I      | II      | III | IV    |
| McLaughlin et al. (2010) | 55                   | 19.3   | 80.7           | 18.3       | 81.7   | 115   | 120       | 346   | 351   | (63)       | 0      | 0      | 112 | 3     | 0      | 112     | 3    | 1     |
| White et al. (2019)   | 45.6                  | 20.5   | 79.5           | 78.2       | 21.8   | 219   | 127       | 216   | 128   | (92.5)     | 9      | 205    | 131 | 1     | 228    | 103     | 0    | 0     |
| Jing et al. (2013)    | 40.6                  | 26     | 74             | 22         | 78     | 233   | 116       | 332.3 | 325.2 | (71.6)     | 0      | 83     | 142 | 0     | 42     | 70      | 0    | 0     |
| Hiremath et al. (2010)| 3                      | 37     | 63             | 43         | 57     | 30    | 14        | -     | -     | (71.4)     | 0      | 0      | 29  | 1     | 0      | 13      | 1    | 0     |
| Simonneau et al. (2012)| 54.8                | 18.2   | 81.8           | 20.8       | 80.2   | 106   | 73        | 118   | 79    | (80.97)    | 0      | 15     | 18  | 0     | 2      | 8       | 0    | 0     |
| Coghlan et al. (2018) | 30                    | 20.1   | 79.9           | 20.8       | 79.2   | 106   | 73        | 118   | 79    | (80.97)    | 0      | 55     | 122 | 0     | 60     | 133     | 0    | 0     |
| Jing et al. (2013)    | 37.3                   | 33     | 67             | 33         | 67     | 5     | 7         | 4     | 2     | (67.3)     | 0      | 8      | 4   | 1     | 4      | 2       | 0    | 0     |
| Gali /C18e et al. (2015)| 5.0                 | 59     | 16             | 15         | 54     | 34    | 25        | 43    | 24    | (77)       | 2      | 42     | 55  | 0     | 3      | 43      | 54   | 2     |
| Gali /C18e et al. (2008)| 45.2                  | 16     | 84             | 12         | 88     | 42    | 25        | 43    | 24    | (77)       | 1      | 20     | 40  | 6     | 2      | 23      | 41   | 1     |
| Gali /C18e et al. (2008)| 45.0                  | 51     | 14             | 32         | 68     | 41    | 22        | 42    | 23    | (84)       | 1      | 28     | 33  | 1     | 34      | 29      | 1    | 0     |
| White et al. (2019)   | 45.6                  | 34     | 66             | 20         | 80     | 253   | 247       | -     | -     | (96)       | 0      | 76     | 177 | 0     | 79      | 168     | 0    | 0     |
| Bermejo et al. (2018) | 70                    | 27     | 73             | 19         | 81     | 104   | 96        | -     | -     | (67)       | 0      | 76     | 177 | 0     | 38      | 88      | 0    | 0     |
| Gali /C18e et al. (2015)| 50                   | 19     | 81             | 20         | 80     | 136   | 95        | 74    | 35    | (73)       | 2      | 42     | 55  | 0     | 3      | 43      | 54   | 2     |
| Rubin et al. (2015)   | 50                    | 16     | 61             | 10         | 54     | 50    | 32        | 54    | 28    | (64)       | 1      | 6      | 4   | 1     | 4      | 2       | 0    | 0     |
| Gali /C18e et al. (2008)| 53                   | 16     | 64             | 12         | 88     | 42    | 25        | 43    | 24    | (77)       | 1      | 20     | 40  | 6     | 2      | 23      | 41   | 1     |
| Gali /C18e et al. (2008)| 50                   | 51     | 14             | 32         | 68     | 41    | 22        | 42    | 23    | (84)       | 1      | 28     | 33  | 1     | 34      | 29      | 1    | 0     |
| White et al. (2019)   | 60                    | 34     | 66             | 20         | 80     | 253   | 247       | -     | -     | (96)       | 0      | 76     | 177 | 0     | 79      | 168     | 0    | 0     |
| Badesch et al. (2006) | 54.2                  | 19     | 81             | 0          | 100    | 17    | 4         | 10    | 1     | (86)       | 0      | 21     | 0   | 0     | 11      | 0       | 0    | 0     |
| Gali /C18e et al. (2008)| 45.2                 | 24     | 76             | 37         | 63     | 54    | 39        | 58    | 34    | (86)       | 0      | 355    | 35  | 0     | 355     | 355     | 0    | 0     |
| Ni (2018)             | 46.8                  | 62     | 38             | 69         | 31     | 0      | 26        | 0     | 26    | (82)       | 318.6   | -      | -   | -     | -      | -       | -    | -     |
| McLaughlin et al. (2015)| 52.9                 | 21.4   | 78.6           | 26.9       | 73.1   | 99    | 60        | 114   | 61    | (78.5)     | 361.3   | 0      | 71    | 88   | 0      | 69      | 104     | 2    | 0     |
| Iversen et al. (2010) | 55.2                  | 26     | 74             | 23         | 77     | 53    | 50        | 354.4 | 350.4 | (73.1)     | 0      | 20     | 29  | 1     | 15      | 38      | 0    | 0     |
## Table 2. Continued.

| First author (year) | Age, years, mean (SD) | Sex, % | Cause of PAH, n | Baseline 6MWD, m Mean (SD) | WHO/NYHA functional class, n |
|---------------------|-----------------------|--------|----------------|--------------------------|-----------------------------|
|                     | Tre                   | Com    | Tre            | Com                      | I   | II  | III | IV  | I   | II  | III | IV  |
| Vizza et al. (2017) | 26.2 (6.4)            | 52     | 31             | 0                         | 0   | 17  | 14  | 0   | 0   | 18  | 12  | 0   |
| Pulido et al. (2013)| 44.5 (16.2)           | 51     | 27             | 0                         | 1   | 258 | 221 | 10  | 0   | 129 | 116 | 4   |
| Sitbon et al. (2019)| 58.0 (8.7)            | 24.6   | 124            | 364                      | 352 | (105.6) | 108.9 | 0   | 3  | 77  | 74  | 2   |
| Jansa and Pulido (2018) | 46.7 (17.0) | 45    | 124            | 385.8                    | 382 | (100) | (108.9) | 0   | 3  | 77  | 74  | 2   |
| De-Zhen and An-Meng (2020) | 11.5 (2.19) | 56    | 64             | 364                      | 343 | (87) | (71) | 0   | 36 | 21  | 3   | 35  | 27  |
| Jian-zhou et al. (2018) | 45.8 (16.3) | 17.9  | 20             | 17.7                     | 21  | 24  | 76  | 27  | 91 | 53  | 48  | 57  | 43  |
| McLaughlin et al. (2006) | 42 (14.4) | 21    | 19             | 317                      | 317 | (74) | (79) | 0   | 76 | 177 | 0   | 79  | 168 |
| Hoeper et al. (2006) | 48 (14.4)            | 26.7   | 43             | 353.5                    | 352 | (87.9) | (91.8) | 0   | 76 | 177 | 0   | 79  | 176 |
| Galli et al. (2015) | 54.5 (14.3)           | 26.4   | 127            | 353.5                    | 354 | (87.9) | (92.3) | 0   | 76 | 177 | 0   | 88  | 80  |
| Badesch (2000)      | 53.0 (10.3)           | 9.1    | 20             | 304.6                    | 290 | (74.1) | (88.5) | 0   | 76 | 177 | 0   | 80  | 80  |
| Barst et al. (1996) | 40 (3)                | 15.8   | 11             | 316                      | 272 | (18) | (23) | 0   | 0  | 26  | 13  | 3   | 7   |
| Barst (1997)        | 37 (15)               | 11     | 12             | 246                      | 205 | (77) | (79) | 0   | 23 | 44  | 0   | 32  | 34  |
| Galli et al. (2002) | 51 (15)               | 19.8   | 24             | 345                      | 345 | (77) | (79) | 0   | 23 | 44  | 0   | 32  | 34  |
| Wilkins et al. (2005) | 41.1 (17) | 17.8  | 11             | 304.6                    | 290 | (74.1) | (88.5) | 0   | 3  | 29  | 9   | 6   | 38  |
| Ronald (2004)       | 54 (2)                | 7.9    | 41             | 280                      | 296 | (13) | (13) | 2   | 41 | 127 | 4   | 31  | 139 |
| Tapson et al. (2012) | 51 (13)               | 50     | 20             | 346.1                    | 345 | (71.4) | (75.5) | 1   | 34 | 88  | 10  | 2   | 34  |
| Simonneau et al. (2014) | 47.8 (12.9) | 18.8  | 23             | 348.9                    | 341 | (71.4) | (77.3) | 0   | 33 | 27  | 0   | 28  | 28  |
| Barst et al. (2003) | 42 (2)                | 13.8   | 16             | 433                      | 445 | (11) | (10) | 0   | 0  | 17  | 5   | 0   | 8   |
| Humbert et al. (2004) | 45 (17)               | 45.5   | 17             | 212.9                    | 219.7 | (55.1) | (35.2) | 0   | 43 | 110 | 3   | 37  | 115 |
| Jian-Yong et al. (2018) | 41 (8)                | 14%    | 86%            | 329.4                    | 336 | (69.2) | (63.5) | 0   | 36 | 21  | 3   | 35  | 27  |
| Tapson et al. (2013) | 51.5 (11)             | 50.4   | 20             | 356                      | 343 | (87) | (71) | 0   | 36 | 21  | 3   | 35  | 27  |
| Zhuang et al. (2014) | 52 (12)               | 23.3   | 60             | 364                      | 364 | (79) | (71) | 0   | 36 | 21  | 3   | 35  | 27  |

(continued)
the SUCRA, Vardenafil (87.2%), Ambrisentan (78.7%) have the highest probabilities of being the best therapeutic options. OR for all-cause death from network meta-analysis were shown in Supplementary Table 8. SUCRA results were demonstrated in Table 3.

Safety outcomes

**AEs**

As far as AEs, a total of 37 studies were included. Compared to Placebo, Ambrisentan combined with Tadalafil (OR, 14.15, 95% CI, 4.07–49.16), Ambrisentan (OR, 5.75, 95% CI, 2.57–12.88), Tadalafil (OR, 4.82, 95% CI, 1.42–16.36), Treprostinil (OR, 3.31, 95% CI, 1.53–7.19) significantly increased the incidence of AEs. According to the SUCRA, Bosentan combined with Sildenafil (84.4%), Macitentan (80.7%), and Sildenafil (77.3%) have the highest probabilities of being the best therapeutic options. OR for AEs from network meta-analysis were shown in Supplementary Table 9. SUCRA results were displayed in Table 3.

**SAEs**

In the case of SAEs, a total of 26 studies were included. There was no statistically significant difference between targeted drugs and Placebo. According to the SUCRA, Ambrisentan (78.9%) and Tadalafil (75.0%) have the highest probabilities of being the best therapeutic options. ORs for SAEs from network meta-analysis were shown in Supplementary Table 10. SUCRA results were displayed in Table 3.

Sensitivity analyses

The sensitivity analyses were consistent with the primary analysis results. The results were shown in Supplementary Table 11.

Discussion

In this network meta-analysis, Bosentan combined with Sildenafil; Sildenafil, Bosentan combined with Iloprost; and Bosentan combined with Tadalafil significantly increased 6MWD. Bosentan combined with Iloprost and Bosentan combined with Sildenafil significantly reduced mPAP. Bosentan combined with Iloprost, and Ambrisentan combined with Tadalafil significantly improved WHO FC. Bosentan combined with Tadalafil and Bosentan combined with Iloprost significantly reduced clinical worsening. Ambrisentan and Ambrisentan combined with Tadalafil significantly increased the incidence of AEs. No treatment regimen has been shown to reduce the incidence of SAEs significantly. Ambrisentan has demonstrated clear benefits in reducing all-cause mortality. Bosentan combined with Sildenafil; Bosentan combined with Tadalafil; Bosentan combined with Iloprost and Sildenafil have relatively good efficacy and safety.
In our study, we found that the combination therapy performed better than placebo in PAH patients at the end of this study, which is in line with previous reviews on the same matter. Still, they are considerably more precise because of our larger quantity of data and resulting statistical power.

At present, combination therapy is not limited to PAH and has been widely used in other chronic diseases such as heart failure (Burnett et al., 2017), hypertension (Paz et al., 2016), tumours (Bennouna and Moreno Vera, 2016) etc. The combination therapy of these patients has a better effect than the single-drug therapy, which may be related to additive or even synergistic effects of the combined treatment against multiple pathways in the pathogenesis of PH. There are at least two benefits of combination therapy: (1) make the treatment reaches the target as soon as possible; (2) reduce the therapeutic dose and minimize AEs. Combination therapies are divided into sequential combination therapy and initial combination therapy. Sequential combination therapy is the most widely used treatment strategy in clinical practice and clinical trials. For patients who have already adopted a treatment plan (using single-drug or even combination therapy), sequential combined treatment is required if they still do not reach a low-risk state. At present, several clinical trials have confirmed that sequential combination therapy can achieve better efficacy than single-drug therapy (McLaughlin et al., 2010; Ghofrani et al., 2013). A meta-analysis that included 4095 PAH patients showed that compared with single-drug therapy, sequential combination therapy reduced the risk of clinical deterioration by 35% (Lajoie et al., 2016). Besides, for this type of treatment, the incidence of additive side effects is lower than the initial combination therapy because the patient must first adapt to the systemic vasodilation effect of one drug before starting another drug.

Consequently, adding therapy to the existing treatment generally results in the same side effect as the initial treatment (Burks et al., 2018). It needs to be managed and monitored when the new therapy is introduced. For the initial combination therapy, it was confirmed for the first time that the WHO FC II–III PAH patients received combination therapy more benefits in the Research of AMBITION in 2015 (Gali et al., 2015). Since then, more and more evidence, including large RCTs, supports initial combination therapy as an effective treatment strategy for PAH (Hassoun et al., 2015; Han et al., 2017; D’Alto et al., 2018). Therefore, the 2018 WORLD SYMPOSIUM ON PULMONARY HYPERTENSION (WSPH) emphasized the importance of combination therapy for PAH patients and recommended low/intermediate/high-risk PAH patients with negative acute vascular reactivity test should first consider the combination of ERA and PDE5i (Qin and Zhi-Hong, 2020). ESC/ERS explicitly recommends the initial combination therapy for high-risk PAH patients, and the treatment should include intravenous prostacyclin analogs. A recent retrospective study found that the triple upfront combination therapy with Ambrisentan, Tadalafil, and subcutaneous Treprostinil significantly improved the clinical and hemodynamics of patients with severe irreversible PAH and was related to right heart reverse remodeling (D’Alto et al., 2020). However, the potential adverse reactions should be considered when using the initial combination therapy for any disease. Although ERA, PDE5i, SGC, and ProsA have different action mechanisms, they can induce vasodilation (Ataya et al., 2016). Thus, compared with monotherapy, the initial combination therapy may cause more AEs.

In terms of outcomes, we found that ERA and PDE5i combined treatments, such as Bosentan combined with Sildenafil, Bosentan combined with Tadalafil, and ERA and ProsA combined treatments, such as Bosentan combined with Ilprost, have a higher probability of more improve 6MWD and cardiac function. Although patients were prone to edema, headache, diarrhea, dizziness, and other adverse reactions (Gali et al., 2008), most patients could tolerate them. Consequently, we considered that ERA combined with PDE5i or ERA combined with ProsA of PAH in the early stage could prevent irreversible remodeling of pulmonary vessels (O’Connell et al., 2013), to get more significant benefits. However, continuous monitoring of blood concentration of patients is needed to judge the progress of PAH (Coghlan et al., 2018) in patients and timely respond to possible AEs when combined treatment regimens are used. Besides, the interaction between drugs should also be considered. For example, the pharmacokinetic interaction between Bosentan and Sildenafil may cause insufficient sildenafil drug plasma concentrations (Grünig et al., 2017). Therefore, the routine...
Figure 3. Network diagrams of comparisons on seven outcomes of different treatments in patients with pulmonary arterial hypertension. (A) 6-Minute Walking Distance (6MWD) Change. (B) Mean Pulmonary Arterial Pressure (mPAP) Change. (C) Clinical worsening. (D) WHO Functional Class (FC) Improvement. (E) Adverse events (AEs). (F) Serious adverse events (SAEs). (G) All-cause mortality. The network plots show how a comparison of different treatments. Each vertex represents a type of treatment vertices’ size represents the intervention sample size. The thickness of the straight line represents the number of trials compared.
monitoring of Sildenafil-Bosentan plasma concentrations is necessary. If patients with inadequate treatment response, the switch from Bosentan to other alternative ERA (Ambrisentan or Macitentan) should be considered (Apitz and Schranz, 2018). However, expect for Sildenafil + Bosentan, Ambrisentan + Tadalafil, different ERA + PDE5i still no RCTs to confirm the efficacy and safety. It is necessary to be cautious in clinical treatment. For patients receiving long-term single-agent therapy (>5–10 years) with stable and low-risk symptoms, Age >75, Suspected pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH), and other patients not recommended to use combined therapy. Although Sildenafil may cause headache, epistaxis, and muscle pain, the benefit of Sildenafil may be more significant. It is crucial to watch the dosage during treatment (Spradley, 2012).

Table 3. Surface under the cumulative ranking curve (SUCRA) results for outcomes.

| Treatment                        | 6MWD change | mPAP change | WHO FC improvement | Clinical Worsening | death | AE | SAE |
|----------------------------------|-------------|-------------|--------------------|--------------------|-------|----|-----|
| Bosentan + Sildenafil             | 0.990       | 0.844       | 0.464              | 0.484              | 0.570 | 0.844 | 0.444 |
| Sildenafil                       | 0.875       | 0.321       | 0.601              | 0.536              | 0.419 | 0.773 | 0.117 |
| Bosentan + Iloprost              | 0.823       | 0.959       | 0.948              | 0.850              | –     | 0.155 | 0.567 |
| Bosentan + Tadalafil             | 0.809       | –           | 0.599              | 0.855              | –     | 0.445 | –    |
| Bosentan                         | 0.700       | 0.613       | 0.457              | 0.692              | 0.641 | 0.751 | 0.251 |
| Epoprostenol                     | 0.631       | 0.453       | –                  | –                  | 0.644 | –    | –    |
| Beraprost                        | 0.513       | 0.230       | 0.412              | 0.563              | 0.632 | 0.043 | 0.587 |
| Ambrisentan + Tadalafil          | 0.426       | –           | 0.757              | 0.563              | 0.632 | 0.043 | 0.587 |
| Riociguat                        | 0.409       | 0.435       | 0.328              | 0.216              | 0.522 | 0.596 | 0.589 |
| Selexipag                        | 0.397       | 0.638       | 0.387              | –                  | 0.225 | 0.669 | 0.609 |
| Macitentan                       | 0.303       | 0.609       | 0.246              | –                  | 0.252 | 0.807 | 0.336 |
| Treprostinil                     | 0.270       | 0.274       | 0.242              | 0.221              | 0.516 | 0.807 | 0.473 |
| Tadalafil                        | 0.177       | –           | –                  | 0.513              | 0.420 | 0.259 | 0.750 |
| Ambrisentan                      | 0.142       | –           | 0.604              | 0.225              | 0.787 | 0.196 | 0.789 |
| Placebo                          | 0.038       | 0.074       | 0.070              | 0.038              | 0.191 | 0.769 | 0.360 |
| Vardenafil                       | –           | 0.549       | 0.749              | 0.806              | 0.872 | 0.364 | –    |
| Bosentan + Epoprostenol          | –           | –           | –                  | –                  | 0.253 | –    | –    |

The surface under the cumulative ranking curve (SUCRA) was used to calculate each intervention’s probability. The larger the SUCRA value, the better the rank of the intervention.

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Author contributions

WF, WH, DX, and CL conceived and designed the study. YL, YC, JL, HL, and LF selected the articles and extracted the data. NR, QJ, and YC wrote the first draft of the article. YS, RM, TW, XW, and NZ interpreted the data and wrote the article’s final version. All authors agreed with the results and conclusions of this article. WF, WH, and CL took responsibility for the integrity of the data and the accuracy of the data analysis, including and especially any adverse effects.

Modification of the protocol

If we need to amend this protocol, we will give the date of each amendment, describe the change and give the rationale in this section. Changes will not be incorporated into the protocol.

Disclosure statement

All authors declare that they have no competing interests.

Funding

This work is supported by the State Key Laboratory of Respiratory Disease (SKLRD-MS-201901), the National Key Research and Development Program of China (2016YFC0901500), and the Construction Plan of High-level University Clinical Research Promotion Plan of Guangzhou Medical University (B185004065).

Data availability statement

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

References

Apitz C, Schranz D. (2018). Sildenafil-Bosentan drug-drug interaction: a word of caution regarding the most common combination therapy in children with advanced pulmonary arterial hypertension. Respiration 96:302.

Ataya A, Cope J, Alnuaimat H. (2016). A review of targeted pulmonary arterial hypertension-specific pharmacotherapy. J Clin Med 5:114.

Badesch D, Bodin F, Channick R, et al. (2002). Complete results of the first randomized, placebo-controlled study of bosentan, a dual...
endothelin receptor antagonist, in pulmonary arterial hypertension. Curr Ther Res 63:227–46.

Badesch DB. (2000). Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 6:425–34.

Barst RJ, McGooin M, McLaughlin V, Tapson V, Oudiz R, Shapiro S, Beraprost Study Group, et al. (2003). Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119–25.

Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group, et al. (2011). Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 30:632–43.

Barst RJ, Rubin LJ, Long WA, et al. (1996). A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334:296–301.

Barst RJ. (1997). Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. Heart 4:299–301.

Baughman RP, Culver DA, Cordova FC, et al. (2014). Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 145:810–7.

Bennouna J, Moreno Vera SR. (2016). Afatinib-based combination regi-

Burks M, Stickel S, Galie N. (2018). Pulmonary arterial hypertension: combination therapy in practice. Am J Cardiovasc Drugs 18:249–57.

Burnett H, Earley A, Voors AA, et al. (2017). Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Heart Fail 10:e003529.

Chetliln MD. (2006). Sildenafil citrate therapy for pulmonary arterial hypertension. Yearbook Cardiol 2006:392–3.

Coghlan JG, Channick R, Chin K, et al. (2018). Targeting the prostacyclin pathway with slexiapag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs 18:37–47.

D’Alto M, Badagliaca R, Argiento P, et al. (2020). Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension. Chest 157:376–83.

D’Alto M, Romeo E, Argiento P, et al. (2018). Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: Clinical and haemodynamic long-term efficacy (ITALY study). J Cardiovasc Med (Hagerstown) 19:12–7.

De-Zhen Z, An-Meng WEI. (2020). Effect of Bosentan combined with tadalafil on activity endurance and cardiac function in patients with pulmonary hypertension. Chinese Journal for Clinicians 48:569–6.

Dodson MW, Brown LM, Elliott CG. (2018). Pulmonary arterial hypertension. Heart Fail Clin 14:255–69.

Galile N, Barbera JA, Frost AE, et al. (2015). Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 373:834–44.

Galile N, , Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al.; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. (2006). Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114:48–54.

Galile N, Brundage BH, Ghofrani HA, et al. (2009). Tadalafil therapy for pulmonary arterial hypertension. Circulation 119:2894–903.

Galile N, Hubbard M, Vachíery JL, Vizza C, Kneusl M, Manes A, Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group, et al. (2002). Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496–502.

Galile N, Rubin LJ, Hoeper MM, et al. (2008). Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. The Lancet 371:2093–100.

Galile N, Müller K, Scalise A-V, Grüning E. (2015). PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J 45:1314–22.

Galile N, Olschewski H, Oudiz RJ, et al. (2008). Ambismentan for the treatment of pulmonary arterial hypertension. Circulation 117:3010–9.

Gao XF, Zhang JJ, Jiang XM, Ge Z, et al. (2017). Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials. PPA 11:871–85.

Gatzoulis MA, , Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, MAESTRO Study Investigators, et al. (2019). Evaluation of macitentan in patients with eisenmenger syndrome. Circulation 139:51–63.

Ghofrani HA, Galile N, Grimminger F, et al. (2013). Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330–40.

Grüning E, Ohnesorge J, Benjamin N, et al. (2017). Plasma drug concentrations in patients with pulmonary arterial hypertension on combination treatment. Respiration 94:26–37.

Han X, Zhang Y, Dong L, et al. (2017). Treatment of pulmonary arterial hypertension using initial combination therapy of bosentan and iloprost. Respir Care 62:489–96.

Hassoun PM, Zamanian RT, Damico R, et al. (2015). Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 192:1102–10.

Hiremath J, Thanhkachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, TRUST Study Group, et al. (2010). Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 29:137–49.

Hoepfer MM, Leuchte H, Halank M, et al. (2006). Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28:691–4.

Hozo SP, Djulbegovic B, Hozo I. (2005). Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13.

Humnet B, Barst RJ, Robbins IM, et al. (2004). Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24:353–9.

Humnet M, Coghlan JG, Ghofrani HA, et al. (2017). Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 76:422–6.

Iversen K, Jensen AS, Jensen TV, et al. (2010). Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blind trial. Eur Heart J 31:1124–31.

Jain S, Khera R, Girota S, et al. (2017). Comparative effectiveness of pharmacologic interventions for pulmonary arterial hypertension: a systematic review and network meta-analysis. Chest 151:90–105.

Jansa P, Pulido T. (2018). Macitentan in pulmonary arterial hypertension: a focus on combination therapy in the seraphin trial. Am J Cardiovasc Drugs 18:1–11.

Jian-Yong ZHU, Yu-Qin ZENG, Qing HU, et al. (2018). Clinical effect of silodosin combined with Bosentan. South China J Cardiovasc Dis 24:40.

Jian-Yong ZHU, Yu-Qin ZENG, Qing HU, et al. (2018). Clinical effect of silodosin combined with Bosentan. South China J Cardiovasc Dis 24:40.

Jing ZC, Yu ZX, Shen JY, et al. (2011). Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 183:1723–9.

Kusunose K, Yamada H, Nishio S, et al. (2019). Pulmonary artery hypertension-specific therapy improves exercise tolerance and outcomes in
exercise-induced pulmonary hypertension. JACC Cardiovasc Imaging 12:2576–9.
Kuwana M, Blair C, Takahashi T, et al. (2020). Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Ann Rheum Dis 79:626–34.
Lajoie AC, Lauziere G, Lega JC, et al. (2016). Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med 4:291–305.
Lin H, Wang M, Yu Y, et al. (2018). Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: a network meta-analysis. Pulm Pharmacol Ther 50:1–10.
Ling-Yun AI, Chen GUO, Yan DING, et al. (2016). Clinical observation of Bosentan combined with Sildenafil in the treatment of congenital heart disease with severe pulmonary arterial hypertension. China Modern Med 23:112–4.
Mbuagbaw L, Rochwerg B, Jaeschke R, et al. (2017). Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev 6:79.
McLaughlin VV, Benza RL, Rubin LJ, et al. (2010). Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 55:1915–22.
McLaughlin V, Channick RN, Ghofrani HA, et al. (2015). Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 46:405–13.
McLaughlin VV, Oudiz R, Frost A, et al. (2006). Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174:1257–63.
Montani D, Chaumais MC, Guignabert C, et al. (2014). Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther 141:172–91.
Ni AI, Wa ER. (2018). To investigate the clinical effect of Bosentan in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Ann Rheum Dis 79:626–34.
Ni AI, Wa ER. (2018). To investigate the clinical effect of Bosentan in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Ann Rheum Dis 79:626–34.
Ni AL, Wa ER. (2018). To investigate the clinical effect of Bosentan in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Ann Rheum Dis 79:626–34.
Paz MA, de-La-Sierra A, Saez M, et al. (2016). Treatment efficacy of antihypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine (Baltimore) 95:e4071
Petrovic M, Locatelli I. (2020). Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis. J Comp Eff Res 9:7–22.
Prins KW, Then appan T. (2016). World Health Organization Group I pulmonary hypertension: epidemiology and pathophysiology. Cardiol Clin 34:363–74.
Pulido T, Adzerikho I, Channick RN, et al. (2013). Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809–18.
Qin LUO, Zhi-Hong LIU. (2020). Principles and progress of targeted drug therapy for pulmonary hypertension. Chin Cirucul J 35:611–4.
Querejeta Roca G, Campbell P, Claggett B, et al. (2015). Right atrial function in pulmonary arterial hypertension. Circ Cardiovasc Imaging 8: e003521.
Ronald JO. (2004). Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2:420–7.
Rosenkranz S, Ghofrani H-A, Beghetti M, et al. (2015). Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart 101:1792–9.
Rubin LJ, Badesch DB, Barst RJ, et al. (2002). Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903.
Rubin LJ, Galie N, Grimminger F, et al. (2015). Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 45:1303–13.